PL431996A1 - Sposób wytwarzania układu zawierającego nanocząstki złota oraz zastosowanie układu zawierającego nanocząstki złota w terapii przeciwnowotworowej - Google Patents

Sposób wytwarzania układu zawierającego nanocząstki złota oraz zastosowanie układu zawierającego nanocząstki złota w terapii przeciwnowotworowej

Info

Publication number
PL431996A1
PL431996A1 PL431996A PL43199619A PL431996A1 PL 431996 A1 PL431996 A1 PL 431996A1 PL 431996 A PL431996 A PL 431996A PL 43199619 A PL43199619 A PL 43199619A PL 431996 A1 PL431996 A1 PL 431996A1
Authority
PL
Poland
Prior art keywords
therapy
containing gold
hours
nanomolecules
obtaining
Prior art date
Application number
PL431996A
Other languages
English (en)
Other versions
PL241754B1 (pl
Inventor
Joanna DEPCIUCH
Justyna MISZCZYK
Magdalena PARLIŃSKA-WOJTAN
Paweł OLKO
Original Assignee
Instytut Fizyki Jądrowej Im. Henryka Niewodniczańskiego Polskiej Akademii Nauk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Fizyki Jądrowej Im. Henryka Niewodniczańskiego Polskiej Akademii Nauk filed Critical Instytut Fizyki Jądrowej Im. Henryka Niewodniczańskiego Polskiej Akademii Nauk
Priority to PL431996A priority Critical patent/PL241754B1/pl
Priority to PCT/PL2020/050085 priority patent/WO2021107794A1/en
Publication of PL431996A1 publication Critical patent/PL431996A1/pl
Publication of PL241754B1 publication Critical patent/PL241754B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Ceramic Engineering (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Przedmiotem wynalazku jest sposób wytwarzania układu zawierającego nanocząstki złota (Au), które w co najmniej 65% wagowych wykazują zasadniczo kształt owalu Cassiniego, o rozmiarach wzdłuż osi podłużnej 55 — 65 nm, wzdłuż osi poprzecznej 24 — 34 nm, a szerokość przewężenia w środkowej części owalu wynosi 22 — 28 nm. Powierzchnia nanocząstek złota jest funkcjonalizowana lekiem przeciwnowotworowym temozolomidem (TMZ), a jako substancję łączącą używa się kwas 16-merkaptoheksadekanowy (MHDA). Wynalazek dotyczy także zastosowania wytworzonego układu w terapii przeciwnowotworowej, zwłaszcza do leczenia nowotworu mózgu o wysokim stopniu złośliwości, jakim jest glejak wielopostaciowy, w połączeniu z radioterapią w zakresie dawek frakcyjnych 0,15 - 15,00 Gy, przy dawce całkowitej do 80 Gy, z uwzględnieniem różnych schematów frakcjonowania. W ciągu całej terapii stosuje się układ w ilości 110 μl na każde 100 - 9000 komórek, a napromienianie prowadzi się do objętości terapeutycznej po upływie 30 minut do 24 godzin od podania układu, przez okres od 15 sekund do 3 godzin.
PL431996A 2019-11-28 2019-11-28 Sposób wytwarzania układu zawierającego nanocząstki złota oraz wytworzony tym sposobem układ zawierający nanocząstki złota do zastosowania w terapii przeciwnowotworowej PL241754B1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL431996A PL241754B1 (pl) 2019-11-28 2019-11-28 Sposób wytwarzania układu zawierającego nanocząstki złota oraz wytworzony tym sposobem układ zawierający nanocząstki złota do zastosowania w terapii przeciwnowotworowej
PCT/PL2020/050085 WO2021107794A1 (en) 2019-11-28 2020-11-20 Method of making a system containing gold nanoparticles and use of the system in antitumor therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL431996A PL241754B1 (pl) 2019-11-28 2019-11-28 Sposób wytwarzania układu zawierającego nanocząstki złota oraz wytworzony tym sposobem układ zawierający nanocząstki złota do zastosowania w terapii przeciwnowotworowej

Publications (2)

Publication Number Publication Date
PL431996A1 true PL431996A1 (pl) 2021-05-31
PL241754B1 PL241754B1 (pl) 2022-11-28

Family

ID=74046109

Family Applications (1)

Application Number Title Priority Date Filing Date
PL431996A PL241754B1 (pl) 2019-11-28 2019-11-28 Sposób wytwarzania układu zawierającego nanocząstki złota oraz wytworzony tym sposobem układ zawierający nanocząstki złota do zastosowania w terapii przeciwnowotworowej

Country Status (2)

Country Link
PL (1) PL241754B1 (pl)
WO (1) WO2021107794A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024015678A1 (en) * 2022-07-13 2024-01-18 Targepeutics, Inc. Methods of treating malignant gliomas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2392528B1 (es) 2010-12-28 2013-10-21 Endor Nanotechnologies, S.L. Sistema de liberación de agente terapéutico, composiciones farmacéuticas que lo contienen, su preparación y su uso médico.
PL408781A1 (pl) 2014-07-07 2016-01-18 Szkoła Główna Gospodarstwa Wiejskiego w Warszawie Zastosowanie nanocząstek metalicznej platyny
WO2017048944A1 (en) * 2015-09-18 2017-03-23 Board Of Regents, The University Of Texas System High-z nanoparticles and the use thereof in radiation therapy

Also Published As

Publication number Publication date
PL241754B1 (pl) 2022-11-28
WO2021107794A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
SG166775A1 (en) Combinations and modes of administration of therapeutic agents and combination therapy
CA2531862A1 (en) Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
MX2009004803A (es) Nanoparticulas de paclitaxel y albumina en combinacion con bevacizumab contra el cancer.
SG11201806438UA (en) Fused Pyrazole Derivatives, Preparation Method Thereof, And Use Thereof In Treatment Of Cancers, Inflammation And Immune Diseases
MX2007003506A (es) Terapia de combinacion de cancer que comprende azd2171 e imatinib.
JP2010523696A (ja) 脳腫瘍を治療する方法
US20150126597A1 (en) Genistein cancer treatment regimen maximizing cancer radiation therapy benefits
SG178942A1 (en) Method of treatment of neurodegenerative or neuro-muscular degenerative diseases and therapeutic agent to treat the same
PL431996A1 (pl) Sposób wytwarzania układu zawierającego nanocząstki złota oraz zastosowanie układu zawierającego nanocząstki złota w terapii przeciwnowotworowej
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
PH12020551715A1 (en) Methods of treating cancer
NO20064755L (no) Kombinasjonsterapi
Chen et al. Cisplatin and albumin-based gold–cisplatin nanoparticles enhance ablative radiation therapy–induced antitumor immunity in local and distant tumor microenvironment
BR0309226A (pt) Métodos para a produção de um efeito de danificação vascular em um animal de sangue quente, e para o tratamento de um câncer envolvendo um tumor sólido em um animal de sangue quente, composição farmacêutica, kit, e, usos de zd6126 ou de um seu sal farmaceuticamente aceitável, e de zd1839 ou de um seu sal farmaceuticamente aceitável
WO2005092384A3 (en) Combination therapy with azd2171 and a platinum anti-tumour agent
Koukourakis et al. Combined Irinotecan, Docetaxel and Conventionally Fractionated Radiotherapy in Locally Advanced Head and Neck Cancer. A. Phase I Dose Escalation Study
BRPI0508983A (pt) uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluido um sal de maleato de azd2171 e um taxano, composição farmacêutica, kit, e, método para a produção de efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente tal como um ser humano
RU2015139515A (ru) Комбинированное лечение
CN1986543A (zh) 癌症化学治疗
Rodda et al. Quality of life outcomes: ASCENDE-RT a multicenter randomized trial of radiation therapy for prostate cancer
JP7105465B2 (ja) キニーネ塩懸濁液を含む抗癌治療のための局所投与用注射剤組成物及び懸濁液注射剤の製造方法
Khadka et al. Metronomic chemotherapy: Low dose less toxic anticancer strategy
CL2024001452A1 (es) Formulaciones inyectables e inhalables
Danping et al. A study on TGC nanomaterials combined with sonodynamic therapy in the treatment of laryngeal cancer
RU2599195C1 (ru) Способ лечения метастатического поражения головного мозга